Walter Schmitt

Summary

Affiliation: Bayer Technology Services GmbH
Country: Germany

Publications

  1. ncbi General approach for the calculation of tissue to plasma partition coefficients
    Walter Schmitt
    Bayer Technology Services GmbH, 51368 Leverkusen, Germany
    Toxicol In Vitro 22:457-67. 2008
  2. ncbi Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs
    Stefan Willmann
    Bayer Technology Services GmbH, Process Technology Systems Biology, Building E41, D 51368 Leverkusen, Germany
    J Pharmacokinet Pharmacodyn 34:401-31. 2007
  3. ncbi A physiologic model for simulating gastrointestinal flow and drug absorption in rats
    Stefan Willmann
    Bayer AG, Bayer Technology Services, Biophysics, 51368 Leverkusen, Germany
    Pharm Res 20:1766-71. 2003
  4. ncbi A physiological model for the estimation of the fraction dose absorbed in humans
    Stefan Willmann
    Bayer Technology Services GmbH, Biophysics, 51368 Leverkusen, Germany
    J Med Chem 47:4022-31. 2004
  5. ncbi A mechanistic approach for the scaling of clearance in children
    Andrea N Edginton
    Competence Center Systems Biology, Bayer Technology Services GmbH, Leverkusen, Germany
    Clin Pharmacokinet 45:683-704. 2006
  6. ncbi From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools
    Stefan Willmann
    Bayer Technology Services GmbH, Process Technology Biophysics, 42096 Wuppertal, Germany
    Expert Opin Drug Metab Toxicol 1:159-68. 2005
  7. ncbi Development and evaluation of a generic physiologically based pharmacokinetic model for children
    Andrea N Edginton
    Competence Center Systems Biology, Bayer Technology Services GmbH, Leverkusen, Germany
    Clin Pharmacokinet 45:1013-34. 2006
  8. ncbi Application of physiology-based pharmacokinetic and pharmacodynamic modeling to individualized target-controlled propofol infusions
    Andrea N Edginton
    Cempetence Center Systems Biology, Bayer Technology Services, Leverkusen, Germany
    Adv Ther 23:143-58. 2006
  9. ncbi Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps
    George Loizou
    Health and Safety Laboratory, Harpur Hill, Buxton, SK17 9JN, UK
    Regul Toxicol Pharmacol 50:400-11. 2008
  10. ncbi Whole body physiologically-based pharmacokinetic models: their use in clinical drug development
    Andrea N Edginton
    University of Waterloo, School of Pharmacy, Waterloo, Ontario, Canada
    Expert Opin Drug Metab Toxicol 4:1143-52. 2008

Detail Information

Publications10

  1. ncbi General approach for the calculation of tissue to plasma partition coefficients
    Walter Schmitt
    Bayer Technology Services GmbH, 51368 Leverkusen, Germany
    Toxicol In Vitro 22:457-67. 2008
    ..For 73% of the calculated values a deviation less than 3-fold from the respective observed value was found, proving the validity of the approach...
  2. ncbi Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs
    Stefan Willmann
    Bayer Technology Services GmbH, Process Technology Systems Biology, Building E41, D 51368 Leverkusen, Germany
    J Pharmacokinet Pharmacodyn 34:401-31. 2007
    ..It is expected that this new tool can be beneficially applied in the planning of clinical studies...
  3. ncbi A physiologic model for simulating gastrointestinal flow and drug absorption in rats
    Stefan Willmann
    Bayer AG, Bayer Technology Services, Biophysics, 51368 Leverkusen, Germany
    Pharm Res 20:1766-71. 2003
    ..The development of a physiologically based absorption model for orally administered drugs in rats is described...
  4. ncbi A physiological model for the estimation of the fraction dose absorbed in humans
    Stefan Willmann
    Bayer Technology Services GmbH, Biophysics, 51368 Leverkusen, Germany
    J Med Chem 47:4022-31. 2004
    ..Cross-validation demonstrated a root-mean-square prediction error of 7% for passively absorbed compounds...
  5. ncbi A mechanistic approach for the scaling of clearance in children
    Andrea N Edginton
    Competence Center Systems Biology, Bayer Technology Services GmbH, Leverkusen, Germany
    Clin Pharmacokinet 45:683-704. 2006
    ..The objective of this research was to develop and evaluate ontogeny models that would provide an assessment of the age-dependence of clearance...
  6. ncbi From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools
    Stefan Willmann
    Bayer Technology Services GmbH, Process Technology Biophysics, 42096 Wuppertal, Germany
    Expert Opin Drug Metab Toxicol 1:159-68. 2005
    ..Some of these models have become commercially available (e.g., GastroPlus: Simulations Plus; PK-Map, PK-Sim: Bayer Technology Services). The contribution of such models to an optimised research and development process will be discussed...
  7. ncbi Development and evaluation of a generic physiologically based pharmacokinetic model for children
    Andrea N Edginton
    Competence Center Systems Biology, Bayer Technology Services GmbH, Leverkusen, Germany
    Clin Pharmacokinet 45:1013-34. 2006
    ....
  8. ncbi Application of physiology-based pharmacokinetic and pharmacodynamic modeling to individualized target-controlled propofol infusions
    Andrea N Edginton
    Cempetence Center Systems Biology, Bayer Technology Services, Leverkusen, Germany
    Adv Ther 23:143-58. 2006
    ..The incorporation of PBPK models may provide target-controlled infusions with enhanced ability to predict response in a wide variety of patients...
  9. ncbi Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps
    George Loizou
    Health and Safety Laboratory, Harpur Hill, Buxton, SK17 9JN, UK
    Regul Toxicol Pharmacol 50:400-11. 2008
    ....
  10. ncbi Whole body physiologically-based pharmacokinetic models: their use in clinical drug development
    Andrea N Edginton
    University of Waterloo, School of Pharmacy, Waterloo, Ontario, Canada
    Expert Opin Drug Metab Toxicol 4:1143-52. 2008
    ....